Osteoporosis and MOTS-C: The Bone Peptide the FDA Is Reviewing

Eighty percent of osteoporosis patients are female. After menopause, women lose bone density at 2 to 3 percent per year for the first 5 to 7 years, driven by estrogen withdrawal. By age 50, roughly 1 in 2 women will experience an osteoporotic fracture in their remaining lifetime. Hip fractures carry a 20 percent mortality rate in the first year.

MOTS-C is a mitochondrial-derived peptide being reviewed by the FDA PCAC on July 23, 2026 for two indications simultaneously: obesity and osteoporosis. The bone indication is why this peptide deserves particular attention from women.

Why Osteoporosis Is Overwhelmingly Female

Women have smaller, thinner bones than men at baseline. Estrogen is a critical regulator of bone remodeling, suppressing osteoclast (bone-resorbing cell) activity while supporting osteoblast (bone-building cell) function. When estrogen drops at menopause, this balance shifts dramatically toward resorption. The result is rapid bone density loss that begins years before most women are aware of it.

Current first-line treatments include bisphosphonates (which slow bone resorption), denosumab (a RANKL inhibitor), and anabolic agents like teriparatide and romosozumab (which stimulate bone formation). HRT also preserves bone density when started early. Despite these options, osteoporosis remains undertreated. Many women are not diagnosed until after a fracture.

What MOTS-C Is

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid peptide encoded by the mitochondrial genome. Unlike most peptides encoded by nuclear DNA, MOTS-C is a retrograde signal from mitochondria to the nucleus. It activates AMPK (AMP-activated protein kinase), a master regulator of cellular energy metabolism.

MOTS-C is naturally present in human blood, but levels decline significantly with age. This decline parallels the age-related declines in metabolic function, insulin sensitivity, and bone density that characterize aging in women.

The Bone Mechanism

MOTS-C's bone-specific effects operate through AMPK activation in osteoblasts and osteoclasts. Preclinical studies show that MOTS-C promotes osteoblast differentiation and activity (building new bone), inhibits osteoclast formation and activity (reducing bone resorption), and improves bone mineral density in animal models of osteoporosis.

The AMPK pathway is particularly interesting because it links metabolic health to bone health. AMPK activation improves insulin sensitivity, reduces inflammation, and promotes cellular energy efficiency. All of these have downstream effects on bone metabolism. For women with both metabolic dysfunction and bone loss (common in PMOS and postmenopause), MOTS-C could theoretically address both conditions through a single mechanism.

The Dual Nomination: Obesity and Osteoporosis

MOTS-C is unique among the seven PCAC peptides in being nominated for two indications. The obesity nomination reflects its AMPK-mediated effects on insulin sensitivity and fat metabolism. The osteoporosis nomination reflects its osteoblast-promoting and osteoclast-inhibiting effects.

This dual nomination is strategically significant. If either indication receives a favorable vote, MOTS-C could be added to the 503A bulks list. The committee may find the evidence stronger for one indication than the other, but approval for either would enable legal compounding for research and clinical use.

The PCAC Vote

MOTS-C is on the July 23 docket (Day 1). The evidence base includes preclinical studies demonstrating bone-protective effects in ovariectomized rodent models (simulating postmenopausal bone loss) and metabolic improvement data. Human clinical trial data is limited, which is the primary risk factor for the vote.

The osteoporosis indication may receive more favorable consideration than the obesity indication because the unmet need is different. Obesity has multiple FDA-approved treatments including GLP-1 RAs. Osteoporosis has fewer anabolic options (teriparatide and romosozumab are the main ones, both expensive and with treatment duration limits). A new anabolic mechanism could fill a genuine clinical gap.

How MOTS-C Compares to Current Treatments

MOTS-C would be positioned differently than existing osteoporosis treatments. Bisphosphonates and denosumab are anti-resorptive (they slow bone loss). Teriparatide and romosozumab are anabolic (they build new bone). MOTS-C, through AMPK activation, appears to do both: promote formation and inhibit resorption. This dual mechanism is conceptually similar to romosozumab but through a completely different molecular pathway.

Additionally, MOTS-C's metabolic benefits could make it particularly valuable for postmenopausal women who have both osteoporosis and metabolic syndrome, addressing two conditions that currently require separate medications.

What This Means for You Now

MOTS-C is not yet approved for any indication. It is available as a research peptide from vendors with appropriate testing documentation. The July 23 vote will determine whether it moves toward legal compounding availability.

If you are concerned about bone health, the evidence-based actions today are: get a DEXA scan (baseline at menopause, earlier if risk factors), ensure adequate calcium (1,200 mg/day) and vitamin D (2,000-4,000 IU/day), do weight-bearing and resistance exercise, discuss HRT for bone protection if appropriate, and talk to your provider about bisphosphonates or anabolic agents if your T-score warrants treatment.

MOTS-C may eventually become part of this toolkit. For now, watch the July 23 vote.